CASES DEATHS CASES DEATHS
December 2020 19,111,443 341,149 2,120,610 24,241
January 26,185,362 441,319 3,310,949 40,702
February 28,602,101 513,137 3,563,578 51,953
March 30,459,874 552,072 3,668,277 59,240
April 32,225,012 574,280 3,742,115 62,078
May 33,261,284 594,468 3,789,227 63,247
June 33,624,871 603,966 3,814,890 63,569
July 34,434,136 610,859 3,903,052 64,231
August 39,057,368 638,700 4,326,204 65,757
September 43,471,906 698,149 4,720,860 69,130
October 45,979,056 746,021 4,915,796 71,950
November 48,214,360 776,586 5,060,666 74,152
December 54,859,966 825,816 5,515,250 76,520
January 74,333,528 884,265 8,292,735 79,801
February 79,025,644 949,957 8,961,636 85,043
March 81,780,503 1,007,320 9,102,677 89,052
April 82,658,881 1,018,326 9,192,666 90,145
UPDATED WEEKLY - Last updated on 22 May 2022, 8:11 am PST, John Hopkins Corona Virus Dashboard and Worldometer
John Hopkins Worldometer
Recovered - Recovered - 97,341,739
POPULATION - is 334,654,677 as of 22 May 2022, 8:11 am PST, based on Census U.S. and World Population Clock.
Cases in the U.S.
Recovered - Recovered - 81,586,249
Cases in California
Recovered - Recovered - 9,035,533
05/22/2022 Cases (WHO) Deaths (WHO) Recovered (WHO)
** no change
*** reporting information is limited, reduced testing and increased cases
United States progress Updated 22 May 2022, 8:11 am PST
Omicron infection induces limited immune response in unvaccinated; COVID hospital deaths rise on weekends. Mon, April 18, 2022, 1:17 PM. Unvaccinated people infected with the Omicron variant are unlikely to develop immune responses that will protect them against other variants of the coronavirus, a new study suggests.
Unlike antibodies induced by COVID-19 vaccines or infections with earlier SARS-CoV-2 variants, antibodies induced by the Omicron BA.1 and BA.2 variants do not neutralize other versions of the virus, researchers found when blood samples were analyzed after an Omicron infection. Those experiencing Omicron "breakthrough" infections after three doses of the mRNA vaccines, designed to neutralize earlier versions of the virus, had high levels of neutralizing antibodies against the two Omicron variants.
The efficiency was lower against previous SARS-CoV-2 versions. But among those whose immune systems had not been primed to recognize the virus through vaccination or by natural infection, antibodies after Omicron infection "were very specific for the respective Omicron variant, and we detected almost no neutralizing antibodies targeting non-Omicron virus strains," said Karin Stiasny and Judity Aberle of the Medical University of Vienna, Austria in a joint email. BA.2-induced antibodies appeared to be particularly unlikely to defend against any other variant, they added. The study "emphasizes the importance of booster vaccinations.
The average number of global deaths from COVID-19 was 6% higher on weekends compared to weekdays throughout the pandemic, according to statistics reported to the World Health Organization between March 2020 and March 2022.
The research found that:
The increase in COVID-19 deaths on weekends may reflect reporting delays, but it also is likely due to hospital staffing levels and other organizational factors, researchers indicated.
What's the new omicron XE variant and should I be worried? APRIL 14, 2022. A "recombinant" variant has emerged, dubbed "omicron XE," the result of two omicron strains merging together in a single host and then infecting others. XE is a recombination of BA.1 and BA.2.
Initially the growth rate for XE appeared not significantly different from BA.2, but more recent data from the UK suggests it has a growth rate of around 10 to 20% above that of BA.2. This data remains preliminary and based on small numbers, so changes may occur as more information is gathered. If it is true, then XE is likely to be more contagious than BA.2, which was more contagious than BA.1, which was more contagious than delta.
While XE still comprises a small proportion of total sequenced cases, showing evidence of community transmission, where it was first detected in England, now has 1,100 cases recorded. It has also been identified in India, China and Thailand.
So what do we know about this new hybrid, and do we need to worry? Omicron has evolved to multiple different lineages or genetically related sub-variants - original omicron BA.1 (B.1.1.529), BA.2 and BA.3. BA.2 is more infectious and the new dominant form of the SARS-CoV-2 virus than BA.1 worldwide.
What's a 'recombinant?' The SARS-CoV-2 virus has continued to change in other ways. A recombinant is when related viruses exchange genetic material to create offspring with genetic material from both parent viruses. The recombinant virus depends on which parts of the genetic material from the parent viruses making a new version. When delta and omicron recombined, the resulting progeny, “deltacron," officially these are referred to as XD and XF.
Do we need to worry? The immune response that helps to protect against COVID-19 is generated by vaccination or from previous infection - mostly targeting the spike protein. XE basically has the same spike protein as BA.2. It doesn't appear protection against XE will be significantly reduced.
The best way to slow the emergence of new variants, as well as recombinants, remains having as many people in the world protected by vaccination to reduce the pool of susceptible hosts in which these events can occur.
New Omicron COVID sub-variant, BA.4 or BA.5, found in Australia in Melbourne wastewater.
Posted Thu 14 Apr 2022 at 10:42pm, Updated Fri 15 Apr 2022 at 12:40am. The sub-variant, which is still to be identified as either BA.4 or BA.5, was found in samples taken from the Tullamarine catchment in the city's north-west.
As of March, the BA.4 sub-variant had been detected in South Africa, Botswana, Denmark and the United Kingdom, while BA.5 cases have been primarily detected in South Africa, with a single case in Hong Kong.
BA.4 and BA.5 strains are still rare, with very few samples of the sub-variant available for epidemiologists to study. The World Health Organization (WHO) said less than 200 sequences of the new strains had been collected.
UPDATE 1-Omicron sub-variant BA.2 makes up 85.9% of COVID variants in U.S. – CDC. Tue, April 12, 2022, 8:17 AM. The U.S. national public health agency said the BA.2 sub-variant of Omicron was estimated to account for 85.9% of the coronavirus variants in the country. A resurgence of COVID-19 cases in parts of Asia and Europe has raised concerns another wave could follow in the United States, but health experts believe it is unlikely.
The U.S. Northeast, including New Jersey, New York and Massachusetts, is the hardest hit region across the country, with Omicron BA.2 now accounting for more than 90% of the cases. Philadelphia, northeastern Pennsylvania, will re-impose its indoor mask mandate from April 18, as a response to a fresh wave of cases. According to a Reuters tally, COVID-19 cases in Pennsylvania have risen 70% within a week, making it among the top 10 states where infections are spreading fastest.
BA.2 made up 75.4% of the variants in the country according to estimates from the U.S. Centers for Disease Control and Prevention, compared with a previous estimate of 72.2%.
Will a New Way to Detect Covid Infections Stop the Next Surge? It could increase testing capacity by roughly 64,000 samples per month. APR 15, 2022 1:02 PM EDT. Until last month, the U.S. was conducting approximately 1.5 million tests a day data from the Covid Tracking Project shows. To contain the spread of the virus, public health experts have repeatedly indicated that widespread testing is the only alternative to mass lockdowns.
With U.S. Covid-19 cases on the rise again, the Food and Drug Administration recently granted emergency use authorization for detecting Covid-19 in breath samples. Research, development and device company, InspectIR Systems's Covid-19 Breathalyzer test, about the size of a piece of carry-on luggage, can provide results in less than three minutes.
The test uses a technique called gas chromatography gas mass-spectrometry, to detect chemical compounds associated with SARS-CoV-2 infection when you exhale or breath out.
This technique is widely used to analyze chemicals, tracking organic pollutants in the environment and monitoring food contamination. InspectIR expects to produce around 100 instruments per week, each used to evaluate approximately 160 samples per day, increasing testing capacity by 64,000 samples per month. In a study of 2409 people, the InspectIR breath test was able to identify 91.2% of the positive test samples accurately.
The White House has warned that without additional funding from the Congress, the federal government will be unable to sustain the testing capacity built over the last 14 months. After spending the last year building up testing capacity, there will be significantly diminished domestic testing capacity and we may be unprepared for surges. "That progress will be squandered, the Administration will be unable to help keep domestic manufacturers online starting in June, the White House spokesperson said.
COVID-19, overdoses pushed US to highest death total ever. Tue, April 12, 2022, 9:05 AM. 2021 was the deadliest year in U.S. history. New data and research are offering more insight. This month’s updated death tally showed 3.465 million deaths last year or about 80,000 more than 2020's record-setting total.
Experts were optimistic 2021 would not be as bad because effective vaccines had finally become available. “We were wrong, unfortunately," said Noreen Goldman, a Princeton University researcher. COVID-19 deaths rose as new variants emerged and an unexpectedly large numbers of Americans refused to get vaccinated or were hesitant to wear masks.
The coronavirus is not solely to blame. Preliminary CDC data also showed:
Experts attributed the spike to fentanyl, a highly lethal drug that has been cut into heroin for several years. More recently it’s also been pressed into counterfeit pills resembling prescription drugs that teens sometimes abuse.
Researchers think U.S. life expectancy dropped five or six months in 2021 — putting it back to where it was 20 years ago. A loss of more than two years of life expectancy over the last two years "is mammoth" Goldman said. “What happened in the U.S. is less about the variants than the levels of resistance to vaccination and public rejection of practices, such as masking and mandates, to reduce viral transmission,” one of the study's authors, Dr. Steven Woolf of Virginia Commonwealth University, said.
COVID-19 vaccines taken by people with inflammatory bowel disease (IBD), which affects millions worldwide, safely and effectively protects them from the SARS-CoV-2 virus, a Rutgers study finds. April 11, 2022. The comprehensive review, published in the journal Alimentary Pharmacology & Therapeutics, focused on all studies describing the response of patients with IBD who were administered a COVID-19 vaccine. People with IBD are commonly treated with drugs that suppress the immune system and have reported concerns over whether such treatments might weaken their response to the vaccine.
"We wanted to demonstrate in a systematic way that the vaccines will safely protect our IBD patients from COVID-19. Our systematic review and meta-analysis confirmed that the vaccines are safe and work well in our patients," said study author Abhishek Bhurwal, an Advanced IBD Fellow in the Division of Gastroenterology and Hepatology at the Rutgers Robert Wood Johnson Medical School.
An estimated 3.1 million adults in the United States have been diagnosed with IBD, which includes Crohn's disease, ulcerative colitis and causes chronic inflammation of the gastrointestinal tract, according to the Centers for Disease Control and Prevention.
The study focused on four key aspects of COVID-19 vaccination of IBD patients:
"Because members of the IBD population are immunocompromised, it was important to document that the SARS-CoV-2 vaccines work for them," Bhurwal said. "With this analysis, we can say that two doses of the SARS-CoV-2 vaccines are safe and effective in the IBD population. But we need further studies regarding booster doses and COVID variants."
UPDATE 1-FDA to discuss Pfizer, Moderna requests for COVID vaccines in young kids in June.
Fri, April 29, 2022, 7:06 AM. An advisory panel of experts will meet in June to review requests from Pfizer Inc. and Moderna Inc. for use of their COVID-19 vaccines in young children, the U.S. Food and Drug Administration said.
The FDA said it would also review Novavax's request for emergency use authorization of its vaccine in individuals 8 and older. Moderna sought authorization for its vaccine for children under the age of 6. Pfizer's primary vaccine is authorized for children aged 5 and older in the United States. Pfizer, expected its latest vaccine data for children under age 5 in April, but said it would complete its submission to regulators for authorization by June. 28% of children 5-to-11 are fully vaccinated in the United States, according to the U.S. Centers for Disease Control and Prevention.
UPDATE 2-Pfizer, BioNTech seek U.S. authorization of COVID-19 booster shot for younger kids.
Tue, April 26, 2022, 1:53 PM. Pfizer/BioNTech SE indicated they submitted an application health for the authorization of a booster dose for children aged 5 to 11 years. Earlier data showing a third dose increased protection against the original coronavirus version and the Omicron variant among children in the age group.
There has also been skepticism on the need for boosters in younger children given the reduced risk of severe infection and hospitalization in the age group. Pfizer/BioNTech have filed for the clearance of a 10-microgram booster dose for children 5 to 11 years. Adults receive a 30-microgram dose of the vaccine. The primary two-dose COVID-19 shot from Pfizer/BioNTech was authorized in October.
How to Protect Yourself? Getting vaccinated is your best bet!
IT’S NOT OVER!
Stay safe. Mask. Social distance. Frequent hand washing. Avoid crowds
ALWAYS CONSULT YOUR PERSONAL HEALTH CARE PROFESSIONAL
1756 N. Riverside Ave
Rialto, CA 92376
Phone: 909 879-1059
Fax : 909 879-1043
Monday 10 am - 4:00 pm Tuesday 10 am - 4:00 pm
Wednesday 10 am - 4:00 pm
Thursday 10 am - 4:00 pm
Friday 10 am - 4:00 pm
HOLIDAY HOURS MAY VARY
10:30 am - 3 pm
Phone orders are encouraged. Large orders prior to 10:30 am
Deliveries not available during covid restrictions.
Stop in to check out all the items currently discounted for your personal resolutions.